An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer
Volume: 22, Issue: 14, Pages: 1815 - 1824
Published: Jul 26, 2021
Abstract
Introduction: Alectinib is a second-generation inhibitor of anaplastic lymphoma kinase (ALK) and RET. Phase III clinical trials have established its superiority to crizotinib in the first-line ALK inhibitor-naïve setting. Studies also support its use over chemotherapy in the post-crizotinib setting. It is currently one of several FDA- and EMA-approved ALK inhibitors, and it is listed as a preferred initial therapy for treatment-naïve...
Paper Details
Title
An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer
Published Date
Jul 26, 2021
Volume
22
Issue
14
Pages
1815 - 1824
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History